Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.
Authors
Tintelnot, JosephXu, Yang
Lesker, Till R
Schönlein, Martin
Konczalla, Leonie
Giannou, Anastasios D
Pelczar, Penelope
Kylies, Dominik
Puelles, Victor G
Bielecka, Agata A
Peschka, Manuela
Cortesi, Filippo
Riecken, Kristoffer
Jung, Maximilian
Amend, Lena
Bröring, Tobias S
Trajkovic-Arsic, Marija
Siveke, Jens T
Zhang, Danmei
Boeck, Stefan
Strowig, Till
Uzunoglu, Faik G
Güngör, Cenap
Stein, Alexander
Izbicki, Jakob R
Bokemeyer, Carsten
Sinn, Marianne
Kimmelman, Alec C
Huber, Samuel
Gagliani, Nicola
Renné, Thomas
Issue Date
2023-02-22Keywords
Pancreatic cancermetagenomic diagnosis
Metadata
Show full item recordJournal
NatureDOI
10.1038/s41586-023-05728-yPubMed ID
36813961PubMed Central ID
PMC9977685Abstract
Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second most deadly cancer by 2040, owing to the high incidence of metastatic disease and limited responses to treatment1,2. Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4, and genetic alterations alone cannot explain this5. Diet is an environmental factor that can influence the response to therapies, but its role in PDAC is unclear. Here, using shotgun metagenomic sequencing and metabolomic screening, we show that the microbiota-derived tryptophan metabolite indole-3-acetic acid (3-IAA) is enriched in patients who respond to treatment. Faecal microbiota transplantation, short-term dietary manipulation of tryptophan and oral 3-IAA administration increase the efficacy of chemotherapy in humanized gnotobiotic mouse models of PDAC. Using a combination of loss- and gain-of-function experiments, we show that the efficacy of 3-IAA and chemotherapy is licensed by neutrophil-derived myeloperoxidase. Myeloperoxidase oxidizes 3-IAA, which in combination with chemotherapy induces a downregulation of the reactive oxygen species (ROS)-degrading enzymes glutathione peroxidase 3 and glutathione peroxidase 7. All of this results in the accumulation of ROS and the downregulation of autophagy in cancer cells, which compromises their metabolic fitness and, ultimately, their proliferation. In humans, we observed a significant correlation between the levels of 3-IAA and the efficacy of therapy in two independent PDAC cohorts. In summary, we identify a microbiota-derived metabolite that has clinical implications in the treatment of PDAC, and provide a motivation for considering nutritional interventions during the treatment of patients with cancer.Item Type
ArticleLanguage
enEISSN
1476-4687ae974a485f413a2113503eed53cd6c53
10.1038/s41586-023-05728-y